Silencing the
virus within
L1 Therapeutics is developing precision therapies that suppress LINE-1 - an ancient virus-like element in the human genome that reactivates under stress and contributes to disease
Targeting LINE-1, an ancient virus-like element in the human genome
When LINE-1 reactivates under stress, it drives genomic instability and an innate immune reaction. Because LINE-1 stays quiet in healthy tissue, inhibitors primarily target disease-causing cells
Therapeutic strategy
New technology now lets us identify diseases where LINE-1 activity is treatable. We focus on conditions that show genomic signs of ongoing, active LINE-1 biology contributing significantly to disease
Genomics, biology, and drug-development specialists
William Brandler
Trained in human genomics with a PhD from the University of Oxford and postdoctoral work at UC San Diego. Over a decade of experience applying large-scale genomic data to disease biology in academia and industry, spanning cancer genomics and computational biology
Prof. Alysson Muotri
Professor at UC San Diego. Leading researcher on neurological disease modeling, brain organoids, and the role of LINE-1 in the brain
Richard Ogden, PhD
Drug development advisor with deep experience guiding small-molecule programs through preclinical and clinical development
Building strategic collaborations
L1 Therapeutics is advancing its therapeutic strategy with the intent to collaborate with pharmaceutical and diagnostics partners on programs across rare neurological disease, oncology, and aging biology
Short reads on LINE-1 biology
Scientific, partnering, or investment inquiries
We welcome conversations with pharmaceutical and diagnostics partners, scientific collaborators, and investors aligned with our mission
info@l1tx.com